Bayesian Capital Management’s Regenxbio RGNX Stock Holding History

Bayesian Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,347	Closed	-$215K	–	1020
2023 Q1	$215K	Buy	+11,347	New	+$251K	0.03%	595
2018 Q2	–	Sell	-7,355	Closed	-$220K	–	705
2018 Q1	$220K	Buy	+7,355	New	+$214K	0.06%	474

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Bayesian Capital Management's RGNX Position: Q2 2023 in Review

Bayesian Capital Management sold out of Regenxbio (RGNX) in Q2 2023, closing a stake of 11,347 shares — an estimated $215K sold.

Bayesian Capital Management first reported a position in RGNX in Q1 2018 and held it in 2 quarters. The position peaked at $220K in Q1 2018. 166 funds tracked by Wall St. Rank hold RGNX as of Q2 2023.

Bayesian Capital Management reported no remaining Regenxbio position as of Q2 2023 after selling out during the quarter.
Bayesian Capital Management sold 11,347 Regenxbio shares in Q2 2023, an estimated $215K.
Bayesian Capital Management first reported a position in Regenxbio in Q1 2018 and held it in 2 quarters.
Bayesian Capital Management's Regenxbio position peaked at $220K in Q1 2018.
166 funds tracked by Wall St. Rank held Regenxbio as of Q2 2023.

Based on Bayesian Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.